Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis.

Skhirtladze C, Distler O, Dees C, Akhmetshina A, Busch N, Venalis P, Zwerina J, Spriewald B, Pileckyte M, Schett G, Distler JH.

Arthritis Rheum. 2008 May;58(5):1475-84. doi: 10.1002/art.23436.

2.

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.

Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S, Distler O.

Arthritis Rheum. 2007 Jan;56(1):311-22.

3.

Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts.

Akhmetshina A, Dees C, Pileckyte M, Szucs G, Spriewald BM, Zwerina J, Distler O, Schett G, Distler JH.

Arthritis Rheum. 2008 Aug;58(8):2553-64. doi: 10.1002/art.23677.

4.

Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.

Avouac J, Palumbo K, Tomcik M, Zerr P, Dees C, Horn A, Maurer B, Akhmetshina A, Beyer C, Sadowski A, Schneider H, Shiozawa S, Distler O, Schett G, Allanore Y, Distler JH.

Arthritis Rheum. 2012 May;64(5):1642-52. doi: 10.1002/art.33501.

5.

The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.

Reich N, Maurer B, Akhmetshina A, Venalis P, Dees C, Zerr P, Palumbo K, Zwerina J, Nevskaya T, Gay S, Distler O, Schett G, Distler JH.

Arthritis Rheum. 2010 Jan;62(1):280-90. doi: 10.1002/art.25056.

6.

A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.

Hasegawa M, Matsushita Y, Horikawa M, Higashi K, Tomigahara Y, Kaneko H, Shirasaki F, Fujimoto M, Takehara K, Sato S.

Arthritis Rheum. 2009 Nov;60(11):3465-75. doi: 10.1002/art.24934.

7.

Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis.

Huber LC, Distler JH, Moritz F, Hemmatazad H, Hauser T, Michel BA, Gay RE, Matucci-Cerinic M, Gay S, Distler O, Jüngel A.

Arthritis Rheum. 2007 Aug;56(8):2755-64.

8.

Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma.

Pannu J, Gardner H, Shearstone JR, Smith E, Trojanowska M.

Arthritis Rheum. 2006 Sep;54(9):3011-21.

9.

Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.

Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, Harigai M, Kamatani N.

Arthritis Rheum. 2004 Jan;50(1):216-26.

10.

MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.

Maurer B, Stanczyk J, Jüngel A, Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, Gay S, Distler O.

Arthritis Rheum. 2010 Jun;62(6):1733-43. doi: 10.1002/art.27443.

11.

Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis.

Hemmatazad H, Rodrigues HM, Maurer B, Brentano F, Pileckyte M, Distler JH, Gay RE, Michel BA, Gay S, Huber LC, Distler O, Jüngel A.

Arthritis Rheum. 2009 May;60(5):1519-29. doi: 10.1002/art.24494.

12.

Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis.

Distler JH, Jüngel A, Pileckyte M, Zwerina J, Michel BA, Gay RE, Kowal-Bielecka O, Matucci-Cerinic M, Schett G, Marti HH, Gay S, Distler O.

Arthritis Rheum. 2007 Dec;56(12):4203-15.

13.

Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse.

Ong VH, Evans LA, Shiwen X, Fisher IB, Rajkumar V, Abraham DJ, Black CM, Denton CP.

Arthritis Rheum. 2003 Jul;48(7):1979-91.

14.

Insulin-like growth factor binding protein 5 induces skin fibrosis: A novel murine model for dermal fibrosis.

Yasuoka H, Jukic DM, Zhou Z, Choi AM, Feghali-Bostwick CA.

Arthritis Rheum. 2006 Sep;54(9):3001-10.

15.

Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.

Yoshizaki A, Yanaba K, Yoshizaki A, Iwata Y, Komura K, Ogawa F, Takenaka M, Shimizu K, Asano Y, Hasegawa M, Fujimoto M, Sato S.

Arthritis Rheum. 2010 Aug;62(8):2476-87. doi: 10.1002/art.27498.

16.
17.

Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells.

Distler JH, Jüngel A, Caretto D, Schulze-Horsel U, Kowal-Bielecka O, Gay RE, Michel BA, Müller-Ladner U, Kalden JR, Gay S, Distler O.

Arthritis Rheum. 2006 Jan;54(1):214-25.

18.

Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts.

Chen Y, Leask A, Abraham DJ, Pala D, Shiwen X, Khan K, Liu S, Carter DE, Wilcox-Adelman S, Goetinck P, Denton CP, Black CM, Pitsillides AA, Sarraf CE, Eastwood M.

Arthritis Rheum. 2008 Feb;58(2):577-85. doi: 10.1002/art.23146.

19.

Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis.

Reich N, Tomcik M, Zerr P, Lang V, Dees C, Avouac J, Palumbo K, Horn A, Akhmetshina A, Beyer C, Xie W, Bennett BL, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2012 May;71(5):737-45. doi: 10.1136/annrheumdis-2011-200412. Epub 2012 Jan 18.

PMID:
22258492
20.

Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.

Pannu J, Asano Y, Nakerakanti S, Smith E, Jablonska S, Blaszczyk M, ten Dijke P, Trojanowska M.

Arthritis Rheum. 2008 Aug;58(8):2528-37. doi: 10.1002/art.23698.

Supplemental Content

Support Center